GlassScriptPhysician profile
Jason W Heil
NPI 1790996007
$3,110.40
in general payments reported to CMS, 2019-2025
26 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $21.03 · 2021: $121 · 2022: $519 · 2023: $702 · 2024: $738 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Education: $4.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.17 |
| Education | $4.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $715.08 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $370.27 | 2024-2025 | Wainua |
| Alexion Pharmaceuticals, INC. | $363.86 | 2019-2024 | Ultomiris, Soliris |
| Sk Life Science, INC. | $347.56 | 2021-2022 | |
| Ucb, INC. | $341.45 | 2023-2025 | Zilbrysq, Rystiggo, Briviact |
| Boston Scientific Corporation | $145.27 | 2023 | Watchman Access System |
| Argenx US, INC. | $143.01 | 2022-2024 | Vyvgart Hytrulo |
| Acadia Pharmaceuticals INC | $103.63 | 2023-2025 | Nuplazid |
| Biogen, INC. | $74.05 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $69.74 | 2025 | |
| Amneal Pharmaceuticals LLC | $62.27 | 2024-2025 | Crexont, Rytary, Brekiya |
| Tg Therapeutics, INC. | $38.82 | 2024-2025 | |
| Eisai INC. | $31.50 | 2025 | |
| Lilly USA, LLC | $30.22 | 2024-2025 | Kisunla, Amyvid |
| Amgen INC. | $28.97 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $28.88 | 2025 | |
| Kyowa Kirin, INC. | $27.08 | 2024 | Nourianz |
| Janssen Pharmaceuticals, INC | $26.42 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.39 | 2024 | |
| Lundbeck LLC | $25.84 | 2025 | Vyepti |
| Genentech USA, INC. | $24.31 | 2025 | Ocrevus |
| Takeda Pharmaceuticals U.S.A., INC. | $22.83 | 2024 | Hyqvia |
| Bioventus LLC | $17.82 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.85 | 2023 | Rexulti |
| Pfizer INC. | $15.67 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Heil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.